MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AML

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses a study (NCT02997202) investigating the efficacy of the FLT3 inhibitor gilteritinib for patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1) following allogeneic stem cell transplantation (alloSCT). While the study did not show overall benefit, it successfully identified patients who benefited most from gilteritinib using measurable residual disease (MRD) assessment. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.